Sugi Predict

Sugi Predict / Compounds / SCHEMBL5656275

SCHEMBL5656275

SCHEMBL5656275

O=C(c1ccc([N+](=O)[O-])cc1)c1ccc2[nH]c(=O)cc(-c3cccc(Cl)c3)c2c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 2/20 0.48
▸ KMT2A Q03164 2/20 0.48
▸ RXFP1 Q9HBX9 1/20 0.48
▸ POLB P06746 2/20 0.45
▸ MAPK1 P28482 1/20 0.45
▸ NPBWR1 P48145 1/20 0.43
▸ FNTA P49354 3/20 0.42
▸ FNTB P49356 3/20 0.42
▸ HCRTR1 O43613 1/20 0.42
▸ PKM P14618 1/20 0.42
▸ MAPT P10636 2/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ TDP1 Q9NUW8 1/20 0.41
▸ CDC25A P30304 1/20 0.40
▸ CDC25B P30305 1/20 0.40
▸ WEE1 P30291 2/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ FASN P49327 1/20 0.39
▸ SRD5A2 P31213 1/20 0.39
▸ CHEK1 O14757 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1538310 0.88 MEN1 (0.59) MEN1KMT2ARXFP1MAPK1FNTA
SCHEMBL5657749 0.84 MEN1 (0.52) MEN1KMT2ARXFP1MAPK1FNTA
SCHEMBL5657976 0.81 MEN1 (0.51) MEN1KMT2ARXFP1MAPK1FNTA
SCHEMBL6009577 0.80 MEN1 (0.49) MEN1KMT2ARXFP1MAPK1FNTA
SCHEMBL5655813 0.78 FNTA (0.48) POLBMAPK1FNTAFNTBMAPT
SCHEMBL5780432 0.78 RXFP1 (0.52) MEN1KMT2ARXFP1MAPK1FNTA
SCHEMBL5722642 0.78 MEN1 (0.52) MEN1KMT2ARXFP1MAPK1FNTA
SCHEMBL5550240 0.77 MEN1 (0.49) MEN1KMT2ARXFP1FNTAFNTB
SCHEMBL7205333 0.77 MEN1 (0.49) MEN1KMT2ARXFP1MAPK1FNTA
SCHEMBL5514658 0.75 MAPT (0.53) MEN1KMT2ARXFP1POLBFNTA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7173040-B2 Farnesyl transferase inhibiting 6-[(substituted phenyl)methyl]-quinoline and quinazoline derinazoline derivatives JANSSEN PHARMACEUTICA N.V. (BE) 2007-02-06 — — US disclosed
US-20040048882-A1 Farnesyl transferase inhibiting 6-(substituted phenyl) Methy)-quinoline and quinazoline derinazoline derivaties JANSSEN-CILAG S.A. (FR) 2004-03-11 — — US disclosed
EP-1322636-A1 FARNESYL TRANSFERASE INHIBITING 6- (SUBSTITUTED PHENYL)METHYL]-QUINOLINE AND QUINAZOLINE DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 2003-07-02 — — EP disclosed
WO-2002024683-A1 FARNESYL TRANSFERASE INHIBITING 6-[(SUBSTITUTED PHENYL)METHYL]-QUINOLINE AND QUINAZOLINE DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 2002-03-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040048882-A1 Farnesyl transferase inhibiting 6-(substituted phenyl) Methy)-quinoline and quinazoline derinazoline derivaties FNTB, FNTA, CYP7A1 MEN1 887/4885KMT2A 1668/4885RXFP1 2024/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.